Medicine
Oxbryta 300 mg tablet
Oxbryta 300 mg tablet is a prescription medicine containing Voxelotor for oral use, marketed by Global Blood Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store OXBRYTA at 20°C to 30°C (68°F to 86°F).
Key facts
- Active ingredient (INN)
- Voxelotor
- Brand
- Oxbryta
- Strength
- 300 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 60 tablets, 90 tablets
- Marketing authorisation holder
- Global Blood Therapeutics
- Manufacturer
- Global Blood Therapeutics
- Origin register
- US FDA, United States
- Storage
- Store OXBRYTA at 20°C to 30°C (68°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- B06AX03 Voxelotor
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 25 November 2019
- Identifiers
- RxCUI 2265683, 2265689, 2588070 +3DailyMed set ID 3c557fac-29ec-483f-b691-8a935d4decc3NDC 72786-102Application NDA213137
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 60 tablet, film coated in 1 bottle, plastic | 72786-102-02 | Global Blood Therapeutics | 14 October 2022 |
| 90 tablet, film coated in 1 bottle, plastic | 72786-102-03 | Global Blood Therapeutics | 14 October 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Voxelotor
Clinical summary
Voxelotor is a hemoglobin S polymerization inhibitor indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 4 years of age and older. It is available as tablets and tablet for oral suspension. MedsAcross supplies Voxelotor for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about VoxelotorFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- OXBRYTA prescribing information (Global Blood Therapeutics) · U.S. National Library of Medicine, DailyMed
Need Oxbryta 300 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.